[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PE20001338A1 - Uso de interleuquina 10 para el tratamiento de infecciones causadas por el virus de la hepatitis c - Google Patents

Uso de interleuquina 10 para el tratamiento de infecciones causadas por el virus de la hepatitis c

Info

Publication number
PE20001338A1
PE20001338A1 PE1999001306A PE00130699A PE20001338A1 PE 20001338 A1 PE20001338 A1 PE 20001338A1 PE 1999001306 A PE1999001306 A PE 1999001306A PE 00130699 A PE00130699 A PE 00130699A PE 20001338 A1 PE20001338 A1 PE 20001338A1
Authority
PE
Peru
Prior art keywords
interleuquin
virus
treatment
hepatic
hepatitis
Prior art date
Application number
PE1999001306A
Other languages
English (en)
Inventor
Paul C Grint
David R Nelson
Gary L Davis
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20001338A1 publication Critical patent/PE20001338A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE AL USO DE INTERLEUQUINA 10 HUMANA O VIRAL Y PUEDE SER UTIL PARA EL TRATAMIENTO DE UNA INFECCION CAUSADA POR EL VIRUS DE LA HEPATITIS C CRONICA; AL MEJORAR LA HISTOLOGIA HEPATICA, PREVENIR LA LESION HEPATICA DEL PACIENTE, FIBROSIS HEPATICA, MEJORAR LA FUNCION HEPATICA, MODULAR LA RESPUESTA INFLAMATORIA Y EL PROCESO DE FIBROSIS RESPONSABLE DE LA DESTRUCCION DEL HIGADO. TAMBIEN SE REFIERE AL USO ADEMAS DE INTERFERON O-2a, O-2b, INTERFERON O 2a o 2b PEG MODIFICADO Y RIBAVIRINA
PE1999001306A 1998-12-22 1999-12-21 Uso de interleuquina 10 para el tratamiento de infecciones causadas por el virus de la hepatitis c PE20001338A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21884298A 1998-12-22 1998-12-22
US29374299A 1999-04-16 1999-04-16
US42571699A 1999-10-22 1999-10-22

Publications (1)

Publication Number Publication Date
PE20001338A1 true PE20001338A1 (es) 2000-12-06

Family

ID=27396589

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999001306A PE20001338A1 (es) 1998-12-22 1999-12-21 Uso de interleuquina 10 para el tratamiento de infecciones causadas por el virus de la hepatitis c

Country Status (7)

Country Link
US (1) US6685931B1 (es)
EP (1) EP1140142A2 (es)
JP (1) JP2002532556A (es)
AU (1) AU2158000A (es)
CA (1) CA2356010A1 (es)
PE (1) PE20001338A1 (es)
WO (1) WO2000037096A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0112119A (pt) * 2000-06-30 2003-05-06 Zymogenetics Inc Polipeptìdeo isolado, molécula de ácido nucléico isolado, vetor, célula hospedeira recombinante, método de produzir a proteìna zcyto21, anticorpo ou fragmento de anticorpo, método de detectar a presença da expressão do gene zcyto21 em uma amostra biológica
GB0024442D0 (en) * 2000-10-05 2000-11-22 Isis Innovation Genetic factors affecting the outcome of viral infections
WO2002032414A2 (en) * 2000-10-18 2002-04-25 Schering Corporation Ribavirin-pegylated interferon alfa hcv combination therapy
US7482149B2 (en) * 2003-06-09 2009-01-27 Genome Institute Of Singapore Inhibition of SARS coronavirus infection with clinically approved antiviral drugs
US7781478B2 (en) * 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) * 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
AU2005275181A1 (en) * 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) * 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7645881B2 (en) * 2004-07-22 2010-01-12 Ptc Therapeutics, Inc. Methods for treating hepatitis C
ES2302402B1 (es) * 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
WO2010149767A1 (en) * 2009-06-25 2010-12-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for determining the risk of occurence of liver fibrosis in an individual
CN102462837B (zh) * 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
EP2937088B1 (en) 2012-12-21 2020-11-18 Tokushima University Composition having tissue repairing activity and utilization thereof
BR112015026122A8 (pt) 2013-04-18 2020-01-21 Armo Biosciences Inc agente de polietileno glicol-il-10 (peg-il-10), seu uso, composição farmacêutica, contentor estéril e kit
EP3434277A1 (en) 2013-06-17 2019-01-30 Armo Biosciences, Inc. Method for assessing protein identity and stability
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
RU2016122957A (ru) 2013-11-11 2017-12-19 Армо Байосайенсиз, Инк. Способы применения интерлейкина-10 для лечения заболеваний и расстройств
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
MX2017004983A (es) 2014-10-22 2017-11-13 Armo Biosciences Inc Metodos para usar interleucina 10 para tratar enfermedades y trastornos.
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10398761B2 (en) 2015-08-25 2019-09-03 Armo Biosciences, Inc. Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0740552A1 (en) 1994-01-20 1996-11-06 Schering Corporation Use of il-10 to stimulate peripheral blood mononuclear cell cytolytic activity
AP690A (en) * 1994-07-05 1998-10-16 Steeno Res Group A/S Immunomodulators based on a polypeptide other than human interleukin 10.
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
ATE262920T1 (de) * 1995-11-02 2004-04-15 Schering Corp Kontinuierliche, niedrigdosierte zytokine- infusionstherapie
AU4385696A (en) * 1996-01-18 1997-08-11 Christian Gronhoj Larsen Synthetic il-10 analogues
CA2253313A1 (en) * 1996-05-02 1997-11-06 Schering Corporation Method for treating or preventing ischemia-reperfusion injury

Also Published As

Publication number Publication date
EP1140142A2 (en) 2001-10-10
CA2356010A1 (en) 2000-06-29
US6685931B1 (en) 2004-02-03
WO2000037096A2 (en) 2000-06-29
JP2002532556A (ja) 2002-10-02
WO2000037096A3 (en) 2000-11-30
AU2158000A (en) 2000-07-12

Similar Documents

Publication Publication Date Title
PE20001338A1 (es) Uso de interleuquina 10 para el tratamiento de infecciones causadas por el virus de la hepatitis c
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
EA200000911A1 (ru) Новые кристаллические формы антивирусного соединения бензимидазола
BR0111195A (pt) Uso de b-l-2'-desoxi-nucleosìdeos no tratamento de infecção por vìrus de hepatite delta
CY2008019I1 (el) Υποκατεστημενες οξαζολιδινονες και η χρηση των στο πεδιο της πηξης αιματος
BR9811121A (pt) Produto, composição farmacêutica, e uso de um produto
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
RU94022480A (ru) Способ лечения гепатита, композиция, усиливающая ин виво инактивацию вируса гепатита с, препарат для лечения гепатита с
BR9913935A (pt) Métodos de tratamento e prevenção de infecção causada por pelo menos um vìrus da famìlia dos flaviviridae e doença associada com a dita infecção em um hospedeiro vivo
CO5050297A1 (es) Uso de peg-ifn-alfa y ribavirina para el tratamiento de hepatitis c cronica
FI935396A (fi) Uudet nanopartikkelien muodossa olevat, veren röntgenvarjoainekoostumukset, joissa on suuren molekyylipainon pinta-aktiivista ainetta
EA200400962A1 (ru) Полиалкиленгликоль с остатком для конъюгации биологически активного соединения
TR200003113T2 (tr) 3-(amino- veya aminoalkil) piridinon türevleri ve bunların HIV bağımlı hastalıkların tedavisinde kullanılması.
NO20034878D0 (no) Antivirale forbindelser
DE69932510D1 (de) Vaskularisierungsinhibitoren
PT1242119E (pt) Combinacoes para o tratamento de infeccoes por virus adn incluindo um diuretico de ansa e um glicosido cardiotonico
ATE394104T1 (de) Adenosin a2a rezeptor-antagonisten zur behandlung und vorbeugung von leberfibrose, zirrhose und fettleber
HUP0200152A2 (hu) KQT1 csatornák gátlóinak alkalmazása parazita férgek és ektoparaziták által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
BR0114814A (pt) Composições compreendendo composto de modafinila e seu uso
WO2002015664A3 (en) Methods of preventing or treating west nile virus and other infections
DE69718156D1 (de) Polypflanzliche pharmazeutische Zusammensetzungen geeignet in der Behandlung der Hepatitis E und Hepatitis B Virus-Infektion zusammenhängenden Zustände
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
ATE544453T1 (de) Kombinationstherapien mit l-fmau zur behandlung von hepatitis-b-virus-infektionen
AR036727A1 (es) Composiciones farmaceuticas para el tratamiento de la fibrosis hepatica y de la infeccion causada por el virus de la hepatitis c y uso de dicha composicion para la manufactura de un medicamento
BR9710206A (pt) Uso de um agente de interleucina-8 e formulação farmacéutica antiviral

Legal Events

Date Code Title Description
FC Refusal